22 Jan 2024 --- Digital healthcare company Noom is partnering with FitOn to launch a “Muscle Defense” addition to its recently launched Noom GLP-1 Companion. Through the extension, Noom aims to help users of glucagon-like peptide-1 (GLP-1) receptor agonist medications navigate muscle mass loss — one of the crucial concerns surrounding the anti-obesity drug. Noom underscores that GLP-1 users risk losing significant muscle mass, strength and bone density if not supported by a strong behavior change program emphasizing muscle-building exercises and a high-protein diet. This can result in lowered resting metabolic rate and worsening insulin resistance.
